Literature DB >> 27207511

Leptin Substitution in Patients With Lipodystrophy: Neural Correlates for Long-term Success in the Normalization of Eating Behavior.

Haiko Schlögl1, Karsten Müller2, Annette Horstmann3, Konstanze Miehle4, Janett Püschel5, Arno Villringer6, Burkhard Pleger7, Michael Stumvoll4, Mathias Fasshauer5.   

Abstract

Lipodystrophy (LD) is a rare disease with a paucity of subcutaneous adipocytes and leptin deficiency. Patients often develop severe diabetes and, additionally, show a disturbed eating behavior with reduced satiety. The disturbed eating behavior can be restored by substitution with the leptin analog metreleptin. Long-term effects of metreleptin on resting state brain connectivity in treatment-naive patients with LD have not been assessed. In this study, resting state functional MRI scans and extensive behavioral testing assessing changes in hunger/satiety regulation were performed during the first 52 weeks of metreleptin treatment in nine patients with LD. Resting state connectivity significantly increased over the course of metreleptin treatment in three brain areas (i.e., hypothalamus, insula/superior temporal gyrus, medial prefrontal cortex). Behavioral tests demonstrated that perceived hunger, importance of eating, eating frequencies, and liking ratings of food pictures significantly decreased during metreleptin therapy. Taken together, leptin substitution was accompanied by long-term changes of hedonic and homeostatic central nervous networks regulating eating behavior as well as decreased hunger feelings and diminished incentive value of food. Future studies need to assess whether metreleptin treatment in LD restores physiological processes important for the development of satiety.
© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27207511     DOI: 10.2337/db15-1550

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  9 in total

Review 1.  What lipodystrophies teach us about the metabolic syndrome.

Authors:  Jake P Mann; David B Savage
Journal:  J Clin Invest       Date:  2019-08-05       Impact factor: 14.808

Review 2.  Update on Therapeutic Options in Lipodystrophy.

Authors:  Baris Akinci; Rasimcan Meral; Elif Arioglu Oral
Journal:  Curr Diab Rep       Date:  2018-10-29       Impact factor: 4.810

3.  Intranasal insulin enhances brain functional connectivity mediating the relationship between adiposity and subjective feeling of hunger.

Authors:  Stephanie Kullmann; Martin Heni; Ralf Veit; Klaus Scheffler; Jürgen Machann; Hans-Ulrich Häring; Andreas Fritsche; Hubert Preissl
Journal:  Sci Rep       Date:  2017-05-09       Impact factor: 4.379

Review 4.  Lipodystrophic syndromes due to LMNA mutations: recent developments on biomolecular aspects, pathophysiological hypotheses and therapeutic perspectives.

Authors:  Corinne Vigouroux; Anne-Claire Guénantin; Camille Vatier; Emilie Capel; Caroline Le Dour; Pauline Afonso; Guillaume Bidault; Véronique Béréziat; Olivier Lascols; Jacqueline Capeau; Nolwenn Briand; Isabelle Jéru
Journal:  Nucleus       Date:  2018-01-01       Impact factor: 4.197

5.  Altered acylated ghrelin response to food intake in congenital generalized lipodystrophy.

Authors:  Camilla O D Araújo; Renan M Montenegro; Amanda P Pedroso; Virgínia O Fernandes; Ana Paula D R Montenegro; Annelise B de Carvalho; Lila M Oyama; Carla S C Maia; Eliane B Ribeiro
Journal:  PLoS One       Date:  2021-01-07       Impact factor: 3.240

6.  Laminopathies' Treatments Systematic Review: A Contribution Towards a 'Treatabolome'.

Authors:  Antonio Atalaia; Rabah Ben Yaou; Karim Wahbi; Annachiara De Sandre-Giovannoli; Corinne Vigouroux; Gisèle Bonne
Journal:  J Neuromuscul Dis       Date:  2021

7.  Rapid response to leptin therapy in a FPLD patient with a novel PPARG missense variant.

Authors:  Fiona Melzer; Corinna Geisler; Dominik M Schulte; Matthias Laudes
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2021-09-01

8.  Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network.

Authors:  Héléna Mosbah; Marie-Christine Vantyghem; Estelle Nobécourt; Fabrizio Andreelli; Francoise Archambeaud; Elise Bismuth; Claire Briet; Maryse Cartigny; Benjamin Chevalier; Bruno Donadille; Anne Daguenel; Mathilde Fichet; Jean-François Gautier; Sonja Janmaat; Isabelle Jéru; Carole Legagneur; Lysiane Leguier; Julie Maitre; Elise Mongeois; Christine Poitou; Eric Renard; Yves Reznik; Anne Spiteri; Florence Travert; Bruno Vergès; Jamila Zammouri; Corinne Vigouroux; Camille Vatier
Journal:  Diabetes Obes Metab       Date:  2022-05-12       Impact factor: 6.408

9.  Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance.

Authors:  Vaia Lambadiari; Aikaterini Kountouri; Eirini Maratou; Stavros Liatis; George D Dimitriadis; Fredrik Karpe
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-08       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.